| HOME >> BIOLOGY >> TECHNOLOGY |
performance of the ongoing operations, adjusted earnings exclude the
impact of discontinued operations
Accounted for as discontinued operations $- $(1)
(b) Net results from operations expected to be divested, net of minority
interest
Other revenue $(6) $(5)
Less:
Cost of sales (6) (4)
Selling, general and administrative (1) (2)
Total $1 $1
To adjust for the results of operations of our non-core DDD&I business
which is expected to be divested. The Company believes adjusting GAAP
earnings for this loss will allow investors to better assess our ongoing
activities.
(c) Amortization and inventory step up adjustments:
Cost of Sales $(52) $(38)
(d) Incremental PLIVA Depreciation due to purchase accounting write up of
fixed assets:
Cost of sales $(7) $(5)
Selling, general and administrative (1) -
Total $(8) $(5)
(e) Write off of acquired IPR&D associated with additional PLIVA shares
$- $(3)
(f) Product settlement - Sanctura $(53) $-
(g) Litigation Reserve $- $(2)
(h) Adjustments to tax expense, including:
Tax impact of adjustments (a) - (g)
above $(5) $13
Tax (benefit) from recognition
of acquired NOL - (3)
Total $(5) $10
EBI
'/>"/>
| SOURCE Barr Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |